Evidence map›Paper›PMID 23562601›Full record

ReviewPharmacology & therapeutics2013

Matrix metalloproteinase (MMP)-9: a proximal biomarker for cardiac remodeling and a distal biomarker for inflammation.

Ganesh V Halade, Yu-Fang Jin, Merry L Lindsey

Abstract readReview
In one paragraph

Review in Pharmacology & therapeutics, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 143 papers.

0numbers the graph read from it
0cells of the map it votes in
143citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

143 citing papers in PubMed.

  1. Trial
  2. Trial
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. The Yin and Yang of copper in cardiovascular health and disease.Molecular and cellular biochemistry · 2026
    Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article

83 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Ganesh V HaladeSan Antonio Cardiovascular Proteomics Center, The University of Texas Health Science Center at San Antonio, United States.
Yu-Fang Jin
Merry L Lindsey

Funding

The Role of Macrophage-derived MMPs in LV RemodelingR01HL075360 · NHLBI · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI LINDSEY, MERRY L. · 2004 to 2018
$5.4M
DHA Mechanisms in Obesity-mediated Cardiac Remodeling Post-Myocardial InfarctionR00AT006704 · NCCIH · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI HALADE, GANESH V · 2013 to 2015
$717k
Effects of Aging on LV Geometry and MMP-9 Expression LevelSC2HL101430 · NHLBI · UNIVERSITY OF TEXAS SAN ANTONIO · PI JIN, YUFANG · 2009 to 2011
$397k
DHA Mechanisms in Obesity-mediated Cardiac Remodeling Post-Myocardial InfarctionK99AT006704 · NCCIH · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI HALADE, GANESH V · 2011 to 2012
$194k
Mathematical Modeling of Matrix Metalloproteinase-9 Driven Left Ventricular RemodR03EB009496 · NIBIB · UNIVERSITY OF TEXAS SAN ANTONIO · PI JIN, YUFANG · 2010 to 2010
$83k
Neutrophil Polarization Following Myocardial InfarctionI01BX000505 · VA · VETERANS HEALTH ADMINISTRATION · PI LINDSEY, MERRY L. · 2009 to 2024
–
BLRD VA I01 BX000505NCCIH NIH HHS K99 AT006704NCCIH NIH HHS K99AT006704NCCIH NIH HHS R00 AT006704NHLBI NIH HHS 1SC2 HL101430NHLBI NIH HHS HHSN268201000036CNHLBI NIH HHS N01-HV-00244NHLBI NIH HHS R01 HL-075360NHLBI NIH HHS R01 HL075360NHLBI NIH HHS SC2 HL101430NIBIB NIH HHS EB009496NIBIB NIH HHS R03 EB009496PHS HHS HHSN 268201000036C
6 · The paper itself

Abstract

Adverse cardiac remodeling following myocardial infarction (MI) remains a significant cause of congestive heart failure. Additional and novel strategies that improve our ability to predict, diagnose, or treat remodeling are needed. Numerous groups have explored single and multiple biomarker strategies to identify diagnostic prognosticators of remodeling progression, which will improve our ability to promptly and accurately identify high-risk individuals. The identification of better clinical indicators should further lead to more effective prediction and timely treatment. Matrix metalloproteinase (MMP-9) is one potential biomarker for cardiac remodeling, as demonstrated by both animal models and clinical studies. In animal MI models, MMP-9 expression significantly increases and is linked with inflammation, diabetic microvascular complications, extracellular matrix degradation and synthesis, and cardiac dysfunction. Clinical studies have also established a relationship between MMP-9 and post-MI remodeling and mortality, making MMP-9 a viable candidate to add to the multiple biomarker list. By definition, a proximal biomarker shows a close relationship with its target disease, whereas a distal biomarker exhibits non-targeted disease modifying outcomes. In this review, we explore the ability of MMP-9 to serve as a proximal biomarker for cardiac remodeling and a distal biomarker for inflammation. We summarize the current molecular basis and clinical platform that allow us to include MMP-9 as a biomarker in both categories.

Indexed as

Ventricular RemodelingAnimalsBiomarkersHumansInflammationMatrix Metalloproteinase 9BiomarkersMatrix Metalloproteinase 9

Identifiers

PMID23562601
PMCPMC3660444

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.